Led by Dr. Xiushan Yin of RocRock Bio, the "Macrophage - based Drug Targeting Solid Tumors" project was included in the innovation projects of the 2023 National Bio - drug Technology Innovation Center's "Cell Therapy 'Revealing the List and Leading the Way' Technology Development Project" on December 8, 2023.
RocRock Bio is China's first company with a macrophage engineering platform powered by gene editing, biomaterials, and synthetic biology. Specializing in macrophage-based solid tumor therapy and clinical application, it drives life science innovation, crafting a unique macrophage-centered closed-loop industry chain. This next-gen cell therapy R & D aligns with China's strategy, boosting independent medical-tech capabilities and bio-medical innovation. RocRock Bio's trailblazing science and cutting-edge tech have earned top attention and recognition from the National Bio-drug Technology Innovation Center.
Dr. Xiushan Yin expressed, "We are deeply honored to be part of the National Bio - drug Technology Innovation Center's cell therapy project. This is both an acknowledgment of our team's achievements in cell therapy and an encouragement for our efforts to drive breakthroughs in solid tumor treatment."
RocRock Bio's macrophage - based drug project for solid tumors focuses on clarifying and verifying CAR-M's efficacy against solid tumors. More importantly, by addressing challenges in macrophage engineering, it facilitates the clinical application of CAR-M therapy, achieving a substantive transition from concept to product. This innovative approach offers cancer patients a more precise and effective treatment option, increasing success rates and reducing side effects.
RocRock Bio's success in a highly competitive review process highlights its strong research and innovation. The project, supported by the National Bio - drug Technology Innovation Center, advances technology development and contributes to the cell therapy field.
Website Builder Software